Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...

Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ESSA Pharma between ...